Acetylon Pharmaceuticals Inc. Company Profile

News Articles [ 22 Associated News Articles listed on BioPortfolio]

Acetylon Nabs $4.9M for Myeloma Drug

Boston-based Acetylon Pharmaceuticals said today it has formed a new alliance with the Leukemia & Lymphoma Society. Under the deal, the nonprofit research foundation will contribute as much as $4....

Acetylon Pharmaceuticals' Selective HDAC Inhibitor Programs to be Featured at the 54th Annual Meeting of the American Society of Hematology

BOSTON--(BUSINESS WIRE)--Nov 20, 2012 - Acetylon Pharmaceuticals Inc., a leader in targeted epigenetic drug discovery and development for enhanced therapeutic outcomes, today announced that its select...

Acetylon, Backed by Patriots Owner Bob Kraft, Snags $27M to Develop New Cancer Drugs

Boston-based Acetylon Pharmaceuticals has been pursuing one of the hottest fields in cancer biology the past couple years, and today it said it was able to scrape together a sizable amount of money to...

Preclinical Results for Acetylon Pharmaceuticals' Selective HDAC1/2 Inhibitor for the Treatment of Sickle Cell Disease and Beta-Thalassemia Presented at ASH 2012

-- Selective HDAC1/2 Inhibition Represents a Novel, Targeted Treatment Approach for SCD and bT -- BOSTON--(BUSINESS WIRE)--Dec 10, 2012 - Acetylon Pharmaceuticals Inc., a leader in targeted epigenetic...

Clinical and Preclinical Results for Acetylon Pharmaceuticals' ACY-1215 for the Treatment of Multiple Myeloma Presented at the 54th Annual Meeting of the American Society of Hematology

-- Selective HDAC6 Inhibitor ACY-1215 Well-Tolerated in Preliminary Phase 1/2 Results and Demonstrates Beneficial Role in Preclinical Models of Multiple Myeloma Bone Disease -- BOSTON--(BUSINESS WIRE)...

Acetylon to Participate on Financing Panel and Provide Corporate Update at BIO Investor Forum

Acetylon Pharmaceuticals today announced that Walter Ogier, President and CEO, will participate on the panel “The New Kids on the Biotech Block: Trends in Early Stage Financingâ...

Acetylon Pharmaceuticals to Present at UBS Global Healthcare Conference

Acetylon Pharmaceuticals Inc., the leader in targeted epigenetic drug discovery and development for enhanced therapeutic outcomes, today announced that Walter C. Ogier, President...

Acetylon Pharmaceuticals Initiates New Phase 1b Clinical Trial of Rocilinostat (ACY-1215) in ...

- Rocilinostat Combination Study with Millennium Takeda’s Velcade® (Bortezomib) and Dexamethasone Advances into Phase 1b -

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [ 3 Associated Companies listed on BioPortfolio]

Acetylon Pharmaceuticals Inc.

Acetylon Pharmaceuticals, Inc. is applying its unique capabilities to discover and develop next-generation, highly selective small molecule drugs to realize the therapeutic potent...

Acetylon Pharmaceuticals, Inc.

Acetylon Pharmaceuticals, Inc. is applying its unique capabilities to discover and develop next-generation, HDAC isoform-selective small molecule drugs to realize the thera...

Acetylon Pharmaceuticals

Acetylon Pharmaceuticals, Inc. is applying its unique capabilities to discover and develop next-generation, highly selective small molecule drugs to realize the therapeutic potent...